James Kasuboski
Partner and Head of Research at Luma Group
Greater Chicago Area
Overview
Work Experience
Partner and Head of Research
2024 - Current
Our team unites a dynamic mix of investors, scientists, clinicians, and entrepreneurs, all dedicated to advancing human health outcomes. We are not just funding remarkable scientific discoveries; we are investing in the future of humanity. Our focus is on nurturing groundbreaking innovations leveraging advanced computation and artificial intelligence that promise to redefine healthcare, ensuring that every investment we make contributes to a healthier, brighter future for all.
Luma Group is an investment firm focused on the intersection of technology-driven life sciences and healthcare companies.
Grant Reviewer
2020
Advisor
2022
Mentor
2019
a collaborative venture program enabling the formation of biotechnology companies addressing climate & sustainability challenges
Co-Founder
2019
Board Member
2019 - 2021
Avilar Therapeutics is a biopharmaceutical company focusing on extracellular protein degradation.
Raised $75,000,000.00 from Medical Excellence Capital, Astellas Venture Management, Sanofi Ventures, RA Capital Management and RA Capital Management.
SBIR/STTR Grant Reviewer
2018
Technology Transfer Center (TTC) facilitates partnerships between the NIH research laboratories and external partners.
Board Member
2021 - 2024
ReAx Biotechnologies uses chemical proteomics to discover small molecule drugs, expanding the targetable proteome.
Board Member
2021 - 2024
Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform.
Raised $7,783,799.00 from stealth.vc.
Biotech Investor at OMX Ventures
2021 - 2024
OMX Ventures is investing at the convergence of biology and computing.
Board Member
2021 - 2023
Seeker Biologics aims to make new medicines for allergic, autoimmune and inflammatory diseases.
Raised $24,100,475.00.